Data Manager

Lindus Health names Heather Davis Vice President of U.S. Clinical Operations. Appointment supports expansion of company's clinical trials footprint in North America. Lindus Health has appointed Heather Davis as Vice President of U.S. Clinical Operations. She will oversee operational teams supporting the company's U.S.-based clinical trial portfolio. The company, headquartered in Boston, has conducted more than 30 U.S. studies across a range of therapeutic areas. Recent examples include a Phase III study with Sooma for a major depressive disorder therapy and a 500-patient study with Cleo related to an ovarian cancer product submission. Davis has more than three decades of experience in clinical research and previously served as Chief Operations Officer at Highline Sciences, where she led operational expansion prior to the firm's acquisition by Tempus. She later became COO of Tempus Compass. "I'm excited to build on that experience at Lindus Health," Davis said. "There is now greater flexibility in how to use technology to expedite clinical research." Lindus Health said the appointment is part of its broader plans to scale staff and delivery capacity in North America.

All-in-One CRO solution Lindus Health welcomes Heather Davis as Vice President of US Clinical Operations. News provided by. BOSTON, Oct. 23, 2025 /PRNewswire/ - Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has announced the appointment of Heather Davis as Vice President (VP) of U.S Clinical Operations. Heather joins the leadership team to scale operational excellence and team capacity across the company's rapidly expanding portfolio of U.S. studies. Headquartered in Boston, Massachusetts, Lindus Health has conducted over 30 studies in the U.S. across multiple indications and therapeutic areas. Notable recent examples include a pivotal Phase III, 200-participant trial with Sooma, intended for FDA submission, for its novel therapeutic approach treating symptoms of major depressive disorder (MDD), and a 500-patient study with Cleo supporting an FDA submission for an ovarian cancer product. The company has partnered with many innovative biotech, pharmaceutical, diagnostic, and medical device companies across North America. To support its continuously growing U.S. presence, Lindus Health has appointed Heather Davis, a seasoned clinical research executive with over 30 years of experience across clinical operations, project management, and executive leadership. Heather was previously the Chief Operations Officer (COO) at Highline Sciences, an oncology-focused CRO, where she helped scale the company from seven employees to over 100, transforming it from a consultancy into a full-service CRO. Following its acquisition by Tempus, Heather remained as the COO of Tempus Compass, leading the integration of technology with clinical operations. "Having seen firsthand how digital tools can streamline trial delivery within CROs, I'm excited to build on that experience at Lindus Health," said Heather Davis, Vice President of U.S. Clinical Operations. "There is now greater flexibility in how to use technology to expedite clinical research and operate more efficiently as a full-service CRO." Heather's unique experience working at biotechs, CROs, and as a research coordinator at sites engaging directly with participants gives her a holistic edge, bringing a deep understanding of the whole stakeholder ecosystem, from sponsors to CROs to sites and patients. Throughout her career, she has worked on studies across various therapeutic areas, including pulmonary, immunology, respiratory, and cardiology, with a focus on oncology over the past decade, spanning from early-phase to global trials. Heather's work in oncology, a research field with stringent regulations that demand operational precision and rigorous standards, underscores her commitment to quality and rigorous excellence. "I was drawn to Lindus Health's one-stop-shop approach and its ability to deliver a fast, robust, tech-forward, and patient-centric all-in-one CRO solution," said Heather. "The company's culture - one that empowers every team member to be the CEO of their project - offers real hope and forward progress for the future of clinical research." As Lindus continues to expand its footprint in North America, Heather's role will be instrumental in building and managing the U.S. teams, while providing end-to-end oversight of high-quality trial delivery, further strengthening the backbone of the company's operations. "Heather's achievements in developing agile, high-performing teams, nuanced expertise in vertical tech integration, and focus on delivering streamlined trials align seamlessly with our company's mission and values," said Emma Ogburn, Senior VP of Clinical Operations at Lindus Health. "We're thrilled to have Heather leading the clinical operations team in the U.S." About Lindus Health Lindus Health is the anti-CRO running radically faster, more reliable clinical trials for life science pioneers - bringing ground-breaking treatments to patients more quickly. By aligning incentives through fixed-price, milestone-based contracts, combining a world-class clinical operations team with a unique software platform, and leveraging access to over 40 million Electronic Health Records, Lindus Health delivers trials designed for speed, reliability, and impact. The company removes the biggest bottleneck in healthcare - clinical trials - through end-to-end study execution powered by technology and forward-thinking approaches to clinical operations. Lindus Health works with leading biotech, medical device, diagnostics, and consumer health companies to accelerate the development of innovative therapies and products. Its impact has been recognized with prestigious accolades, including the Fierce Biotech CRO Awards for Outstanding Patient Recruitment and Retention and inclusion in the PM360 Elite 100. To date, Lindus Health has delivered trials across the US, UK, and Europe in conditions ranging from diabetes and asthma to major depressive disorder, hypertension, and chronic fatigue syndrome. The company has raised over $80M from investors including Balderton, Peter Thiel, Creandum, Firstminute Capital, and Seedcamp. Media Contact: Jodi Perkins Amendola Communications on behalf of Lindus Health [email protected] SOURCE Lindus Health

Lindus Health partners with Yendou to streamline site engagement and accelerate clinical trial feasibility. BOSTON, Oct. 16, 2025 - Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, has announced a partnership with Yendou, an AI powered site engagement and management platform. This collaboration streamlines site outreach and data management for stronger and more efficient site dynamics using an automated and scalable all-in-one site platform with site database, automated feasibility workflows, and survey build features. Site feasibility is a key part of clinical trials and the work that CROs facilitate for each study. This process involves gathering information from sites regarding their therapeutic expertise, access to patient populations, staff qualifications, contracting timelines and other relevant capabilities. Unfortunately, most CROs adopt a transactional approach with sites and lack centralized data systems, forcing teams to resend the same questionnaires and re-enter information manually, even for familiar sites. This outdated approach inflates timelines and hinders meaningful relationships with sites. The partnership between Lindus Health and Yendou provides a central location for long-term memory storage of site data that is usually fragmented across multiple channels. Using Yendou, Lindus Health can send out surveys once to obtain site demographics and store it to be accessed for future trials by all team members. With persistent memory, Yendou will also automatically reuse historical answers to questions in all subsequent surveys. This means sponsors receive quicker answers to RFPs, CROs can spend more time on other trial activities, and sites are not overworked with repetitive questioning. Lindus Health consolidates previously separate tools into Yendou's single platform, enabling individualized outreach (versus clunky BCC email chains), open visibility into individual sites within partner networks, and automated onboarding with intro, capabilities, and NDA workflows. What sets Yendou apart is its ability to measure the speed and quality of site engagement across every interaction. By transforming communication and responsiveness into structured intelligence, Yendou enables Lindus Health to build a personalized, data-driven ranking of sites based on their own performance - not on market benchmarks. Over time, this internal site intelligence allows Lindus to anticipate which sites will activate fastest and deliver most reliably, turning feasibility into a continuously improving system. By increasing communication and transparency, Lindus and its sites are building stronger, more trusted relationships. Early data of this partnership revealed time savings of more than six hours per FTE per week, previously consumed by manual tasks. Now, powered by automation and persistent memory, Lindus Health can focus on connection-building interactions, including increased site calls, early Principal Investigator (PI) input on studies to support protocol development, and transparent pipeline visibility. The outcomes of this partnership speak for themselves with 394% more qualified sites and 15x more investigators in just eight weeks, broadening trial reach and capabilities. Additionally, more thorough and detailed feasibility assessments that directly guide the trial are achieved through 12x more data points per site. The site network has not only gotten bigger, but the relationships have also gotten stronger. "At Lindus Health, we've seen that when sites feel valued as strategic partners, everything changes - trust deepens, loyalty strengthens, and response times accelerate," said Meri Beckwith, Co-CEO of Lindus Health. "Partnering with Yendou helps make that possible." This collaboration strengthens Lindus' ability to deliver robust end-to-end clinical trials through one unified solution. To learn more about Lindus Health's capabilities, click here. About Lindus Health Lindus Health is the anti-CRO running radically faster, more reliable clinical trials for life science pioneers - bringing ground-breaking treatments to patients more quickly. By aligning incentives through fixed-price, milestone-based contracts, combining a world-class clinical operations team with a unique software platform, and leveraging access to over 40 million Electronic Health Records, Lindus Health delivers trials designed for speed, reliability, and impact. The company removes the biggest bottleneck in healthcare - clinical trials - through end-to-end study execution powered by technology and forward-thinking approaches to clinical operations. Lindus Health works with leading biotech, medical device, diagnostics, and consumer health companies to accelerate the development of innovative therapies and products. Its impact has been recognized with prestigious accolades, including the Fierce Biotech CRO Awards for Outstanding Patient Recruitment and Retention and inclusion in the PM360 Elite 100. To date, Lindus Health has delivered trials across the US, UK, and Europe in conditions ranging from diabetes and asthma to major depressive disorder, hypertension, and chronic fatigue syndrome. The company has raised over $80M from investors including Balderton, Peter Thiel, Creandum, Firstminute Capital, and Seedcamp.